Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Inhibition of phosphatidylinositol 3-kinase (PI3K) is a promising approach to overcome resistance to endocrine therapy in breast cancer. Pictilisib is an oral inhibitor of multiple PI3K isoforms. The aim of this study is to establish if addition of pictilisib to fulvestrant can improve progression-free survival in oestrogen receptor-positive, endocrine-resistant breast cancer.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Jun 2016

Volume: 17

Issue: 6

Affiliations

[1 ] Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: ian_krop@dfci.harvard.edu.

[2 ] Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

[3 ] Peninsula Oncology Centre, Melbourne, VIC, Australia.

[4 ] Memorial Sloan Kettering Cancer Center, New York, NY, USA.

[5 ] The Royal Marsden Hospital, London, UK.

[6 ] Hospital Arnau de Vilanova, Lleida, Spain.

[7 ] Sarah Cannon Research Institute, and Tennessee Oncology, Nashville, TN, USA.

[8 ] Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.

[9 ] University of Alabama, Birmingham, AL, USA.

[10 ] National University Hospital, Singapore.

[11 ] Royal Melbourne Hospital, Parkville, VIC, Australia.

[12 ] Masaryk Memorial Cancer Institute, Brno, Czech Republic.

[13 ] Herlev University Hospital, Copenhagen, Denmark.

[14 ] Mayo Clinic, Jacksonville, FL, USA.

[15 ] Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

[16 ] Washington University School of Medicine, St Louis, MO, USA.

[17 ] Dana-Farber Cancer Institute, Boston, MA, USA.

[18 ] Genentech, South San Francisco, CA, USA.

[19 ] Barts Cancer Institute, Queen Mary University of London, London, UK.

Article

Publisher Item ID: S1470-2045(16)00106-6

DOI: 10.1016/S1470-2045(16)00106-6

PubMed ID: 27155741

SO-VID: fd49ab42-20c0-46f8-b07e-81dbd6cabf8a

History

Data availability:

Comments

Comment on this article

scite_

Cited by 114

See all cited by

- Version 1
- Version 1